Literature DB >> 8693108

Late renal function following whole abdominal irradiation.

C Irwin1, A Fyles, C S Wong, C M Cheung, Y Zhu.   

Abstract

Sixty patients treated with whole abdominal radiotherapy who had remained disease-free since completion of treatment participated in a study to assess the late clinical and biochemical effects of bilateral renal irradiation. Minimum follow-up was 5 years with a maximum of 20 years and a median of 9 years. Fifty-two patients in the study group were treated for primary ovarian cancer. Seven had non-Hodgkins lymphoma arising in the gastrointestinal tract and one patient had a carcinoid tumour arising in small bowel. None of the patients received chemotherapy. Abdominal radiation was given using an open beam technique to a mean dose of 22.92 Gy (range 6.68-27.54 Gy) in 1.02 to 1.25 Gy fractions treated once daily. Posterior kidney shields were used in order to limit the renal dose to < 20 Gy. Mean radiation dose to both kidneys (retrospectively calculated) was 19.28 Gy (range 6.68-22.99 Gy). Patients ranged in age from 32-81 years with a median of 61 years. No patient had clinical evidence of renal impairment. Nine patients were hypertensive prior to radiotherapy and a further five patients became hypertensive after treatment. Serum creatinine values ranged from 44-123 mumol/l, with a mean of 87 mumol/l. Creatinine clearance ranged from 0.61-2.38 ml/s (mean 1.28 ml/s). Tubular function tests revealed one borderline high 24-h protein excretion and normal 24-h phosphorous and uric acid. Using a multiple linear regression analysis with creatinine clearance as the endpoint, age was the only significant variable (P < 0.00001) and renal dose and interval from treatment were not independently significant. There was no evidence of late renal toxicity more than 5 years after whole abdominal radiotherapy delivered with this technique and dose/fractionation schedule, and using the clinical and biochemical endpoints assessed in this study.

Entities:  

Mesh:

Year:  1996        PMID: 8693108     DOI: 10.1016/0167-8140(95)01702-x

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  2 in total

1.  Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation Therapy.

Authors:  Thomas H Beckham; Dana L Casey; Michael P LaQuaglia; Brian H Kushner; Shakeel Modak; Suzanne L Wolden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-04-11       Impact factor: 7.038

2.  Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: a clinical phase I/II study.

Authors:  J L Casey; M P Napier; D J King; R B Pedley; L C Chaplin; N Weir; L Skelton; A J Green; L D Hope-Stone; G T Yarranton; R H J Begent
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.